Ki-67 Proliferative Marker in Lymph Node Aspirates of Patients with Non-Hodgkin's Lymphoma

Mihaljević, B.; Nedeljkov-Jancic, Ruzica; Cemerikic-Martinovic, Vesna; Babić, Dragan; Čolović, M

doi:10.1385/mo:23:1:83

Cited by 8 publications

(5 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding low expression of Ki-67 in this study in NHL patients and intermediate grade histopathologic type , these results may indicate that those patients were with long survival rate and this may agreed with (8).…”

Section: Disscussionsupporting

confidence: 68%

“…lignant hematological disorders, including non-Hodgkin's lymphomas (NHL) .Ki-67 is used as prognostic factor in NHL and it differentiate indolent from aggressive disease (7) , (8).High Ki-67 antigen expression has been repeatedly described in Hodgkin's and Reed-Sternberg cells (9). Hall 1988 (4) and Hussainand Harris2006 (10),made clinical classification of non-Hodgkin's lymphomas into high-and low-grade lymphomas which was shown to be mirrored by differences in Ki-67 staining.…”

Section: Iraqi Journal Of Cancer and Medical Geneticsmentioning

confidence: 99%

See 1 more Smart Citation

Expression of Ki67and p53 Proteins in Hodgkin ׳s Lymphomas and Non Hodgkin׳s Lymphomapatients using immunohistochemistry

Alaswad¹,

Abdulmohymen²,

Ghazi³

2018

IJCMG

View full text Add to dashboard Cite

Background: Hodgkin’s lymphoma (HL) and Non-Hodgkin’s lymphoma( NHL) are characterized by a profound disturbance of the cell cycle and apoptosis regulation., Ki-67 and P53 expression has been shown to be associated with adverse clinical outcome in a variety of malignant hematological disorders, including HL and NHL. Aim: This study aimed to clarify Ki-67 expression level and its correlation with p53 expression in HL and NHL. Material and methods: total of 28 newly diagnosed HL and NHL patients were investigated for Ki-67 expression and its correlation to p53 expression by immunohistochemical technique. Results: Ki-67 expression was observed in 46.7 % of HL patients while 7.7% of NHL patients gave positive Ki-67 expression. A significant Association between thetype of lymphoma and Ki67 expression (p<0.05) noticed. The histopathologcal type appeared to be 57.1% mixed cellularity and 37.5% of them showed positive Ki67 expression , while 42.9 % were intermediate grade and only 16.7 % showed positive Ki67 expression . There were no significant correlation between the histopathologcal type and Ki67 expression. only 4 ( 14.3 %) of the cases were p53 negative ,while the rest 24 cases were p53 positive ,and the majority ( 66.7% ) were within score 2 . Eight cases ( 28.6 %) were positive for Ki-67 and p53 , Ki-67 was negative in 71.4% cases , and four of them were negative for p53 and the rest 16 ( 80% )cases were p53 positive .A significant correlation was found between p53 and Ki-67 expression where( r=0.608,p=0.001) . conclusion : it is suggested that immunohistochemical studies of p53 and Ki-67 expression in tumor tissue including HL and NHL can help in monitoring of patients at risk, and the markers may aid in controlling the progression of lymphoma and detect the degree of aggressiveness of the disease to give suitable treatment and management of patients .

show abstract

Section: Disscussionsupporting

confidence: 68%

Section: Iraqi Journal Of Cancer and Medical Geneticsmentioning

confidence: 99%

Expression of Ki67and p53 Proteins in Hodgkin ׳s Lymphomas and Non Hodgkin׳s Lymphomapatients using immunohistochemistry

Alaswad¹,

Abdulmohymen²,

Ghazi³

2018

IJCMG

View full text Add to dashboard Cite

show abstract

“…Previous efforts to find diagnostic factors for NHL have yielded disappointing results compared with studies reporting prognostic factors with clinicopathological correlations [5,6]. Our previous study showed that the urine level of IL-8 normalized to creatinine could be a possible biomarker with the capacity to discriminate NHL patients from normal controls; thus, we expected that urine might be a valuable biological source for diagnostic markers for NHL [7].…”

Section: Discussionmentioning

confidence: 96%

Identification of hypoxanthine as a urine marker for non-Hodgkin lymphoma by low-mass-ion profiling

Yoo

Kong²,

Jang

et al. 2010

BMC Cancer

View full text Add to dashboard Cite

BackgroundNon-Hodgkin lymphoma (NHL) is a hematologic malignancy for which good diagnostic markers are lacking. Despite continued improvement in our understanding of NHL, efforts to identify diagnostic markers have yielded dismal results. Here, we translated low-mass-ion information in urine samples from patients with NHL into a diagnostic marker.MethodsTo minimize experimental error, we tested variable parameters before MALDI-TOF analysis of low-mass ions in urine. Urine from 30 controls and 30 NHL patients was analyzed as a training set for NHL prediction. All individual peak areas were normalized to total area up to 1000 m/z. The training set analysis was repeated four times. Low-mass peaks that were not affected by changes in experimental conditions were collected using MarkerView™ software. Human Metabolome Database (HMDB) searches and ESI LC-MS/MS analyses were used to identify low-mass ions that exhibited differential patterns in control and NHL urines. Identified low-mass ions were validated in a blinded fashion in 95 controls and 66 NHL urines to determine their ability to discriminate NHL patients from controls.ResultsThe 30 highest-ranking low-mass-ion peaks were selected from the 60-urine training set, and three low-mass-ion peaks with high intensity were selected for identification. Of these, a 137.08-m/z ion showed lower mass-peak intensity in urines of NHL patients, a result that was validated in a 161-urine blind validation set (95 controls and 66 NHL urines). The 130.08-m/z ion was identified from HMDB searches and ESI LC-MS/MS analyses as hypoxanthine (HX). The HX concentration in urines of NHL patients was significantly decreased (P < 0.001) and was correlated with the mass-peak area of the 137.08-m/z ion. At an HX concentration cutoff of 17.4 μM, sensitivity and specificity were 79.2% and 78.4%, respectively.ConclusionsThe present study represents a good example of low-mass-ion profiling in the setting of disease screening using urine. This technique can be a powerful non-invasive diagnostic tool with high sensitivity and specificity for NHL screening. Furthermore, HX identified in the study may be a useful single urine marker for NHL screening.

show abstract

“…Since some types of B-NHL can exhibit different clinical behaviors, it is necessary to identify rapid clinical progression as early as possible and adjust treatment accordingly ( 32 , 33 ). It is particularly important to identify patients with indolent lymphoma but is high risk for transformation lymphoma because aggressive therapy can alter the treatment outcome ( 34 ). Previous studies have demonstrated that the Ki67 index is one of the most useful indicators for the early recognition of disease progressionand for detecting the transformation of indolent lymphoma to aggressive lymphoma before it is evident in clinical manifestation ( 34 ).…”

Section: Discussionmentioning

confidence: 99%

“…It is particularly important to identify patients with indolent lymphoma but is high risk for transformation lymphoma because aggressive therapy can alter the treatment outcome ( 34 ). Previous studies have demonstrated that the Ki67 index is one of the most useful indicators for the early recognition of disease progressionand for detecting the transformation of indolent lymphoma to aggressive lymphoma before it is evident in clinical manifestation ( 34 ). In our research, we analyzed the positive rate of Ki67 in 42 patients with indolent lymphoma transformation.…”

Section: Discussionmentioning

confidence: 99%

Multicolor flow cytometric assessment of Ki67 expression and its diagnostic value in mature B-cell neoplasms

Mao

Li²,

Liu³

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

BackgroundThere is no unified standard data about the sensitivity and specificity regarding flow cytometry analysis of Ki67 expression during lymphoma diagnoses.ObjectiveThis evaluated the efficacy of multicolor flow cytometry (MFC) in an estimate of the proliferative activity of B-cell non-Hodgkin lymphoma by comparing the expression of Ki67 using MFC and immunohistochemicals (IHC).MethodA total of 559 patients with non-Hodgkin B-cell lymphoma were immunophenotyped using sensitive MFC, of which 517 were newly diagnosed and 42 were transformed lymphomas. Test samples include peripheral blood, bone marrow, various body fluids, and tissues. Through MFC multi-marker accurate gating, abnormal mature B lymphocytes with restricted expression of the light chain were screened. Ki67 was added to determine the proliferation index; the positive rate of Ki67 in tumor B cells was evaluated by cell grouping and internal control. For tissue specimens, MFC and IHC analyses were performed simultaneously to assess the Ki67 proliferation index.ResultsThe positive rate of Ki67 by MFC was correlated with the subtype and aggressiveness of B-cell lymphoma. Ki67 could distinguish indolent lymphomas from aggressive subtypes with a cut-off value of 21.25%, and differentiate transformation from indolent lymphoma with a cut-off value of 7.65%. The expression of Ki67 by MFC (regardless of the type of samples)was highly agreement with the Ki67 proliferative index of tissue samples assessed by pathologic immunohistochemistry. MFC showed a fairly constant negative bias in evaluating tissue or bone marrow samples, compared with IHC.ConclusionsKi67 is a valuable flow marker that can distinguish between indolent and aggressive types of lymphoma and assess whether indolent lymphomas are transformed. Using MFC to evaluate the positive rate of Ki67 is important in clinical settings. MFC has unique advantages in judging the aggressiveness of lymphoma in samples of bone marrow, peripheral blood, pleural and ascites, and cerebrospinal fluid. This is particularly important when tissue samples cannot be obtained, making it an important supplement for pathologic examination.

show abstract

Ki-67 Proliferative Marker in Lymph Node Aspirates of Patients with Non-Hodgkin's Lymphoma

Cited by 8 publications

References 20 publications

Expression of Ki67and p53 Proteins in Hodgkin ׳s Lymphomas and Non Hodgkin׳s Lymphomapatients using immunohistochemistry

Expression of Ki67and p53 Proteins in Hodgkin ׳s Lymphomas and Non Hodgkin׳s Lymphomapatients using immunohistochemistry

Identification of hypoxanthine as a urine marker for non-Hodgkin lymphoma by low-mass-ion profiling

Multicolor flow cytometric assessment of Ki67 expression and its diagnostic value in mature B-cell neoplasms

Contact Info

Product

Resources

About